On the other hand, epidermal growth factor receptor gene (EGFR) mutations are important in the pathogenesis of lung adenocarcinoma and EGFR tyrosine kinase inhibitor (EGFR TKI) treatment has been shown to significantly prolong survival of patients with lung adenocarcinoma with EGFR mutations4. The gene discussed is EGFR; the disease is lung adenocarcinoma.